Ocular Therapeut (OCUL) Stock Price, Quote & News

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 357 4000

Website: www.ocutx.com

Address:

15 Crosby Drive, Bedford, United States

Merlintrader Mar. 21 at 8:41 PM

$OCUL https://www.merlintrader.com/ocular-therapeutics-inc-feb25-update/

0 · Reply

WarrenDouglasTrader Mar. 21 at 8:16 PM

$OCUL Any timeline ideas for a catalyst? With technicals destroyed, this just keeps dropping otherwise.

1 · Reply

Night_Owl_Biotech Mar. 21 at 4:53 PM

$SNDX is the best performing comm'l-stage bio stock (in both oncology & non-oncology) as measured by its 3/20/26 close v. its 3.5 month high (since 12/1/25). The attachment lists all 92 commercial-stage oncology (MCs over $300MM) & non-oncology (MCs over $900MM) bio stocks 3/20/26 closing share price v. their 3.5 month high (again since 12/1/25). The table excludes DAWN & DVAX (both recently acquired). The $XBI is more or less unchanged over this time (up 0.5%) Note more than half of SNDX peers are off their recent highs by over 25%. $BCRX comes a close second to SNDX. BCRX's strong share price is likely due to the Betaville Uncooked alert this last week suggesting BCRX is in active M&A negotiations. $KNSA ranks third on the list $OCUL 's share price appears to provide a textbook example of why the odds are shareholder value is maximized via M&A exit in this peer group. As always, do not rely on the attachment. Verify the data points for yourself. This is not investment advice.

1 · Reply

kundalini56 Mar. 21 at 4:02 PM

$OCUL Lawsuit by EYPT--it is a competitive tactic by EYPT to Delay OCUL from filing the paperwork with FDA to get Axpaxli. From available data it is clear EYPT is behind a year or more . OCUL's street talks would have coached by their legal team- so this lawsuit is frivolous at best. Institutions and the general market will through this tactic. At the end of the day, Axpaxli will be approved in 2026 and beat EYPT to the market by a year or more-- this is our conclusion after reviewing all available reports on these two competitors. We feel this situation is similar to Ozempic and Wygovy. In our view, both companies should get their share of the market. GL all OCUL longs.

2 · Reply

Thundr1 Mar. 21 at 3:37 PM

$OCUL Commercial disparagement lawsuit, not a data or FDA challenge, classic playbook when a competitor is on the back foot and trying to disrupt momentum rather than invalidate the science. Bullish

0 · Reply

Harvo Mar. 21 at 2:16 PM

$OCUL Jay Duker is lashing out in desperation with this lawsuit.

1 · Reply

rizzato Mar. 21 at 12:33 PM

$OCUL someone sold someone bought but mostly they are still there https://www.nasdaq.com/market-activity/stocks/ocul/institutional-holdings

2 · Reply

BuyoutBobby Mar. 21 at 7:56 AM

$OCUL if you want a data point from one of the best biotech investors then look at The Column Group. They were holding over 6 million shares of OCUL but sold them all in Q4 and started buying Surrozen shares. Now they are holding around 30% of Surrozen and no OCUL shares.

1 · Reply

kundalini56 Mar. 21 at 4:04 AM

$OCUL We are adding to our "substantial" holding on all dips. This is definitely a long-term investment. This meets our criteria (Institutional--very heavy; 11 Analysts- rated mod buy or strong buy; 1-year target- $18- $30; Axpaxli- well differentiated drug- passed the tests in flying colors; lots of cash in hand (to last thru 2018). And now, just saw the news of an Institution taking a big position at $11.69. As saying goes-follow Vanguard- as for as long-term investment is concerned. Cantor Fitzgerald L. P. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm purchased 201,865 shares of the biopharmaceutical company's stock, valued at approximately $2,360,000 ($11.69 per share). Unless you disagree on facts here, do not waste your time bashing this poster. GL longs.

1 · Reply

JaimieB3666 Mar. 20 at 10:20 PM

$OCUL truth is an absolute defense to libel. As long as OCUL can back up its claims with science, this is free advertising for us

1 · Reply

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

EYPT

Mar 9, 2026, 4:01 PM EDT - 12 days ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 2, 2026, 4:37 PM EST - 18 days ago

Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript

Feb 19, 2026, 10:41 AM EST - 4 weeks ago

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 17, 2026, 4:15 PM EST - 4 weeks ago

Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript

Feb 17, 2026, 7:08 AM EST - 4 weeks ago

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

REGN

Feb 13, 2026, 5:00 PM EST - 5 weeks ago

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Feb 6, 2026, 4:01 PM EST - 6 weeks ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 4, 2026, 7:30 AM EST - 6 weeks ago

Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive

Dec 8, 2025, 12:59 PM EST - 3 months ago

Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug

Nov 4, 2025, 3:16 PM EST - 4 months ago

Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:05 AM EST - 4 months ago

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 7:00 AM EST - 4 months ago

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Oct 7, 2025, 7:00 AM EDT - 5 months ago

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Oct 1, 2025, 4:22 AM EDT - 6 months ago

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript

Sep 30, 2025, 7:08 AM EDT - 6 months ago

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Sep 30, 2025, 6:21 AM EDT - 6 months ago

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Sep 8, 2025, 5:05 PM EDT - 6 months ago

Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 7, 2025, 1:52 AM EDT - 6 months ago

Ocular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of Care

Aug 5, 2025, 1:33 PM EDT - 8 months ago

Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript

Jun 26, 2025, 1:54 PM EDT - 9 months ago

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Jun 16, 2025, 7:00 AM EDT - 9 months ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

May 14, 2025, 7:00 AM EDT - 11 months ago

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Mar 11, 2025, 2:49 PM EDT - 1 year ago

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Mar 6, 2025, 11:15 AM EST - 1 year ago

Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential

Mar 3, 2025, 10:16 AM EST - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Feb 3, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Jan 14, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Dec 30, 2024, 12:16 PM EST - 1 year ago

Ocular Is Now Thoroughly Derisked

Dec 10, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 2, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Nov 26, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Nov 14, 2024, 10:34 AM EST - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Nov 6, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Oct 11, 2024, 5:50 AM EDT - 1 year ago

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

AMD

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at September Retina Meetings

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Aug 9, 2024, 12:53 PM EDT - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 7:10 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Jul 31, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Jun 20, 2024, 9:13 AM EDT - 1 year ago

This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

SWKS BFH IRTC TRU

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Merlintrader Mar. 21 at 8:41 PM

$OCUL https://www.merlintrader.com/ocular-therapeutics-inc-feb25-update/

0 · Reply

WarrenDouglasTrader Mar. 21 at 8:16 PM

$OCUL Any timeline ideas for a catalyst? With technicals destroyed, this just keeps dropping otherwise.

1 · Reply

Night_Owl_Biotech Mar. 21 at 4:53 PM

1 · Reply

kundalini56 Mar. 21 at 4:02 PM

2 · Reply

Thundr1 Mar. 21 at 3:37 PM

$OCUL Commercial disparagement lawsuit, not a data or FDA challenge, classic playbook when a competitor is on the back foot and trying to disrupt momentum rather than invalidate the science. Bullish

0 · Reply

Harvo Mar. 21 at 2:16 PM

$OCUL Jay Duker is lashing out in desperation with this lawsuit.

1 · Reply

rizzato Mar. 21 at 12:33 PM

$OCUL someone sold someone bought but mostly they are still there https://www.nasdaq.com/market-activity/stocks/ocul/institutional-holdings

2 · Reply

BuyoutBobby Mar. 21 at 7:56 AM

1 · Reply

kundalini56 Mar. 21 at 4:04 AM

1 · Reply

JaimieB3666 Mar. 20 at 10:20 PM

$OCUL truth is an absolute defense to libel. As long as OCUL can back up its claims with science, this is free advertising for us

1 · Reply

blackboxlabel Mar. 20 at 10:04 PM

$OCUL https://finance.yahoo.com/news/eyepoint-sues-rival-ocular-therapeutix-212601717.html

1 · Reply

azv134 Mar. 20 at 9:22 PM

THIS MARKET CRASH IS PERFECT TO MAKE THE FOLLOWING STOCKS MY CORE POSITIONS IN 2026 $ABEO $HROW $AQST $OCUL Aiming for ~ 15% allocation of my portfolio in each company.

0 · Reply

rabbitsoup Mar. 20 at 9:02 PM

$OCUL $EYPT is suing $OCUL for defamation and misleading claims

9 · Reply

Kylea1 Mar. 20 at 8:40 PM

$OCUL this market environment isn’t exactly friendly for buyouts

1 · Reply

WarrenDouglasTrader Mar. 20 at 8:21 PM

$OCUL This is broken....technicals now super bearish. Buyout speculation dead.

0 · Reply

kundalini56 Mar. 20 at 4:37 PM

$OCUL Thanks all those who opened the eyes to the potential here for those willing to weather the storms along the way. Look forward to an UP day for OCUL today despite the War & the overall market conditions. Thinking very positive and we are adding in any dips. Look forward to postings from all LONGS. Always trying accept what is beyond control-- wars, economy among others. Good luck LONGS.

1 · Reply

Nosh Mar. 20 at 2:07 PM

$OCUL Had starter...large add here...gl.

0 · Reply

Dy2ski Mar. 20 at 12:38 PM

$OCUL In addition to all the lovely BS swirling around the markets, we have Triple Witching today.

0 · Reply

Porsh408 Mar. 20 at 9:39 AM

$OCUL OMG!

0 · Reply

Porsh408 Mar. 20 at 9:34 AM

$OCUL Oh hay!!! I been busy this week, missing out on some interesting stuff hidden in the whole stock market being down..

1 · Reply

Porsh408 Mar. 20 at 9:17 AM

$OCUL Morning guys! Happy Triple Witching Friday! Max pain strike price is currently $9.00. Lets go! 💪

1 · Reply

WarrenDouglasTrader Mar. 19 at 8:28 PM

$OCUL Gave up weekly 200ma, screwed for forseeable future. Dammit.

0 · Reply

Market Cap	1.85B
Revenue (ttm)	51.95M
Net Income (ttm)	-265.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-511.92%
Debt to Equity Ratio	0.11

Volume	4,158,400
Avg Vol	6,947,164
Day's Range	N/A - N/A
Shares Out	217.69M
Stochastic %K	7%
Beta	0.91
Analysts	Strong Sell
Price Target	$24.85